SCHEMBL2945771

SCHEMBL2945771

Fc1cc2c(-c3ccncc3)n[nH]c2cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.49
MKNK1 Q9BUB5 1/20 0.49
PDPK1 O15530 2/20 0.44
CDK2 P24941 2/20 0.44
MAP2K4 P45985 2/20 0.44
DCLK1 O15075 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
CHEK2 O96017 1/20 0.44
CSF1R P07333 1/20 0.44
FER P16591 1/20 0.44
MARK3 P27448 1/20 0.44
FLT4 P35916 1/20 0.44
FLT3 P36888 1/20 0.44
MAPK9 P45984 1/20 0.44
CSNK1D P48730 1/20 0.44
CLK2 P49760 1/20 0.44
CSNK2A1 P68400 1/20 0.44
CSNK1G2 P78368 1/20 0.44
MAP4K2 Q12851 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14015807 0.81 NTRK1 (0.52) NTRK1MKNK1PDPK1CDK2MAP2K4
SCHEMBL11970930 0.80 ADORA2A (0.47) PDPK1CDK2MAP2K4CHEK1CDK1
SCHEMBL2941886 0.77 KDR (0.45) CDK2MAP2K4DCLK1PRKD3MAP4K4
SCHEMBL10112175 0.77 DYRK1A (0.58) NTRK1MKNK1PDPK1CDK2MAP2K4
SCHEMBL23830502 0.75 PDPK1 (0.36) PDPK1MAP2K4JAK2MAP2K7
SCHEMBL30536586 0.75 PDPK1 (0.36) PDPK1MAP2K4JAK2MAP2K7
SCHEMBL2731639 0.75 FLT3 (0.75) NTRK1MKNK1PDPK1CDK2MAP2K4
SCHEMBL2946762 0.74 TDO2 (0.45) NTRK1MAP2K4LRRK2CHEK1MAPK1
SCHEMBL19533700 0.73 MAP2K4 (0.47) MKNK1CDK2MAP2K4DCLK1PRKD3
SCHEMBL17678215 0.73 PDPK1 (0.34) PDPK1MAP2K4JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750026-B2 Fused heteroaryl derivatives and their use as p38 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-07-06 US disclosed
US-7750026-B2 Fused heteroaryl derivatives and their use as p38 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-07-06 US disclosed
US-7750026-B2 Fused heteroaryl derivatives and their use as p38 kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-07-06 US disclosed
EP-1709028-B1 FUSED HETEROARYL DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2008-11-05 EP disclosed
US-20070054942-A1 Fused heteroaryl derivatives and their use as p38 kinase inhibitors GLAXOSMITHKLINE LLC 2007-03-08 US disclosed
US-20070054942-A1 Fused heteroaryl derivatives and their use as p38 kinase inhibitors GLAXOSMITHKLINE LLC 2007-03-08 US disclosed
US-20070054942-A1 Fused heteroaryl derivatives and their use as p38 kinase inhibitors GLAXOSMITHKLINE LLC 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054942-A1 Fused heteroaryl derivatives and their use as p38 kinase inhibitors MAPK1, MAPK7, MAPKAPK2 NTRK1 1943/4885MKNK1 68/4885PDPK1 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.